title: Vincristine sulfate liposome injection: a guide to its use in refractory or relapsed acute lymphoblastic leukemia.
abstract: Adult patients with acute lymphoblastic leukemia frequently relapse or are refractory to conventional treatments. The vincristine sulfate liposome injection (Marqibo(®)) encapsulates the drug in a liposome composed of sphingomyelin and cholesterol to improve tumor drug exposure. At a dose of 2.25 mg/m(2) once weekly, this formulation was associated with an overall response rate of 35 % in adults with Philadelphia chromosome-negative relapsed or refractory disease. There were no new or unexpected toxicities.
authors: Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand.
authors: Tracy S
authors: TS
authors: Harrison
authors: Katherine A
authors: KA
authors: Lyseng-Williamson
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002784:Cholesterol / Q000737:chemistry; D002986:Clinical Trials as Topic; D004337:Drug Carriers / Q000737:chemistry; D006801:Humans; D007262:Infusions, Intravenous; D008081:Liposomes; D017410:Practice Guidelines as Topic; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D055502:Secondary Prevention; D013109:Sphingomyelins / Q000737:chemistry; D014018:Tissue Distribution; D014750:Vincristine / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D004337:Drug Carriers; D008081:Liposomes; D013109:Sphingomyelins; D014750:Vincristine; D002784:Cholesterol